Abstract: 2-(2'-Naphthyl) acetaldehyde derivatives optionally substituted at the 2 position and/or positions C-1',4',5',7' or 8'; and/or position C-6' or positions C-5' and 7' exhibit anti-inflammatory, analgesic, antipyretic and anti-pruritic activity.

Abstract: A method for lowering elevated serum lipid concentrations comprising administering a composition containing, as the active ingredient, a 3.beta. -substituted-16.alpha.-cyanopreg-5-en-20-one wherein the substituent at the 3.beta.-position is selected from the group consisting of hydroxy, alkoxy having 1 to 6 carbon atoms, cycloalkoxy having 3 to 6 carbon atoms, acyloxy wherein the acyl moiety has 2 to 7 carbon atoms, tetrahydrofuran-2'-yloxy, tetrahydropyran-2'-yloxy, and 4'-alkoxytetrahydropyran-4'-yloxy where the alkoxy moiety has 1 to 6 carbon atoms. Representative active ingredients are 3.beta.-acetoxy-16.alpha.-cyanopreg-5-en-20-one and 3.beta.-cyclopentyloxy-16.alpha.-cyanopregn-5-en-20-one. These representative agents are also useful in the therapeutic method of protecting and regenerating damaged hepatic tissue.

Abstract: Novel 2-substituted-1,2,4-thiadiazolo-[ 2,3-a]-benzimidazoles of the formula ##SPC1##And the pharmaceutically acceptable salts thereof; and process for their preparation. These 2-substituted-1,2,4-thiadiazole-[2,3-a]-benzimidazoles are useful as fungistatic and fungicidal agents.

Abstract: This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.

Abstract: Novel 4-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]- and 5-[2,3 or 4(3-amino-2-hydroxypropoxy) phenyl]-1,2,3-thiadiazole derivatives which may be further substituted at the C-5 or C-4 position of the thiadiazole ring, respectively, by a lower alkyl, phenyl, trifluoromethyl, carboxy, alkoxycarbonyl, cyano or an aminocarbonyl group, and the pharmaceutically acceptable acid addition salts thereof and processes for the production of such compounds; 4-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole and 5-[4(3-t-butylamino-2-hydroxypropoxy)phenyl]-1,2,3-thiadiazole are representative of the class. These compounds possess cardiovascular activity and are useful for the treatment of abnormal heart conditions in mammals.

Abstract: An inhalation device having an elongate housing having one or more passageways for the passage of air therethrough. Each passageway, of relatively small diameter, opens into an emptying chamber, of relatively greater diameter, adjacent that end of the housing which is adapted for insertion into the mouth or nose of a user. Adjacent that end of the emptying chamber closest to the passageway(s), the housing has means for receiving or presenting a unit dose of powdered medicament for administration. During inhalation, the air stream passing over and directed into the powdered medicament holder entrains the powdered medicament which is then carried into the nose, throat or lungs of the user where beneficial or therapeutic action of the medicament occurs.

Abstract: This application describes analgesic formulations including d 2-(6-methoxy-2-naphthyl)propionic acid, or a pharmaceutically acceptable salt or ester thereof, in combination with at least one central nervous system active analgesic compound. Analgesic activity of the combination is greater than that obtained with either of the components alone, thus demonstrating enhanced analgesia which can be obtained therewith.

Abstract: Benzene ring substituted benzimidazole-2-carbamate derivatives represented by the formula: ##SPC1##Where R is a lower alkyl group having 1 to 4 carbon atoms; R.sup.1 is a heterocyclic ring having 1-4 hetero atoms; and M is O, S, or ##EQU1## The R.sup.1 M-substitution is at the 5(6)-position. The compounds are useful as pesticides, particularly as anthelmintic and antifungal agents.

Abstract: A novel class of intermediates from which a variety of uronic acid nucleosides can be produced, said class being represented by the following formula: ##SPC1##WhereR.sub.1 and R.sub.2 are lower alkyl radicals having one to six carbon atoms, or phenyl radicals;R.sub.3 is a lower alkyl radical having one to four carbon atoms; and the wavy line at the 5' position indicates both the 5'-D-allo and 5'-L-talo epimers.A process for producing these intermediates is described. A process for converting these intermediates to uronic acid nucleosides having the following formula: ##SPC2##WhereB is a pyrimidine or purine base, is also described.Novel uronic acid nucleosides, having structures falling within the general formula given above, are identified.

Abstract: Novel 8R-antimeric and racemic 11.alpha.-methylsubstituted-prosta-5-cis, 13-trans-dienoic and prost-13-trans-enoic acids having oxygenated functions at the C-9 and C-15 positions of the molecule, as well as the 15-methyl or ethyl derivatives thereof and processes for making such compounds. Also encompassed are the pharmaceutically acceptable, non-toxic alkyl esters and salts of the carboxylic acid function of these novel compounds.

Abstract: 2-(2'-Naphthyl) acetaldehyde derivatives optionally substituted at the 2 position and/or positions C-1',4',5',7' or 8'; and/or position C-6' or positions C-5' and 7' exhibit anti-inflammatory, analgesic, antipyretic and anti-pruritic activity.

Abstract: Process for degrading the glycoside neriifolin and its acetate to the cardenolide digitoxigenin. Novel intermediates are also described.

Abstract: This invention relates to a topical, anti-inflammatory, pharmaceutical composition which comprises (a) a pharmaceutically acceptable solvent, e.g. propylene glycol and water, and (b) at least two corticosteroids chosen from those represented by formulas A through K defined hereinafter, each corticosteroid dissolved in said solvent at a concentration equal to the saturation solubility for each steroid. Other suitable pharmaceutical formulation additives may be added to prepare the desired type of formulation, e.g. cream, ointment, lotion, or gel. The invention includes a process for preparing the compositions and a method for treating inflamed skin conditions using the novel compositions.

Abstract: This invention relates to a method of fertility control by use of novel cyclic progestogen-interrupted estrogen oral contraceptive regimens. Considering the first day of menstrual flow as day one of a 28 day medication administration cycle, a combined formulation of estrogen and progestogen substances is administered on the 3rd, 4th, 5th or 6th day of the cycle and every second or third day thereafter through, and including, the 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle, and a formulation having only a progestogen substance as the active component is administered on the 4th, 5th, 6th, or 7th day of the cycle and every day thereafter on which a combination formulation is not administered, through, and including, the 22nd, 23rd, 24th, 25th, 26th, 27th or 28th day of the cycle.

Abstract: Novel process for the preparation of 11.alpha.-hydroxymethyl derivatives of natural (8R-) and racemic 9-keto-15.alpha.-hydroxy- and 9,15.alpha.-dihydroxy-prosta-5-cis,13-trans-dienoic and prost-13-transenoic acids, and the novel 15-methyl and ethyl substituted derivatives thereof, as well as the esters of the primary and secondary hydroxy groups and the non-toxic, pharmaceutically acceptable salts of the novel compounds.

Abstract: 10.alpha.-Hydroxy-11-desoxy-prostaglandin analogs of the PGE.sub.1 and PGE.sub.2 and PGF.sub.1.sub..alpha. and PGF.sub.2.sub..alpha. series, the 11-dehydro derivatives thereof as well as the 9,10-ketals in the PGF series, and methods of preparing same, 9-keto-10.alpha.,15.alpha.-dihydroxyprosta-13-trans-enoic or 5-cis,13-trans-dienoic acid, 9.alpha.,10.alpha.,15.alpha.-trihydroxyprosta-11,13-trans-dienoic or 5-cis, 11,13-trans-trienoic acid and 9.alpha.,10.alpha.-isopropyli-denedioxy-15.alpha.-hydroxyprosta-13-trans-e noic or 5-cis,13-trans-dienoic acid are representative of the class. Also included are the corresponding pharmaceutically acceptable, non-toxic esters, ethers and salts. These compounds possess prostaglandin-like activity and thus are useful in the treatment of mammals, where prostaglandins are indicated.